The Medical Letter on Drugs and Therapeutics: Difference between revisions
Randykitty (talk | contribs) merge discontinued journal here |
No edit summary |
||
| Line 14: | Line 14: | ||
| CODEN = MELEAP |
| CODEN = MELEAP |
||
}} |
}} |
||
'''''The Medical Letter on Drugs and Therapeutics''''' is a peer-reviewed biweekly medical publication that provides critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases. |
|||
'''''The Medical Letter on Drugs and Therapeutics''''' (commonly referred to as ''The Medical Letter'') is a [[Peer review|peer-reviewed]] biweekly [[medical journal]] providing evaluations of [[pharmaceutical drug]]s. It is published in English, French, and Italian [[The Medical Letter, Inc.]], which also publishes the monthly ''[[Treatment Guidelines from The Medical Letter]]''. the journal is abstracted and indexed in [[Index medicus]]/[[MEDLINE]]/[[PubMed]]. An offshoot, ''Treatment Guidelines from The Medical Letter'' ({{ISSN|1541-2792}}) was published from 2002-2014, when it was integrated into this journal. |
|||
== Editorial process == |
== Editorial process == |
||
The first draft of an article is prepared by one of our in-house or contributing editors or by an outside expert. This initial draft is edited and sent to our Contributing Editors, to 10-20 other reviewers who have clinical and/or experimental experience with the drug or type of drug or disease under review, to the FDA, and to the first and last authors of all the articles cited in the text. Many critical observations, suggestions, and questions are received from the reviewers and are incorporated into the article during the revision process. Further communication as needed is followed by fact checking and editing to make sure the final appraisal is not only accurate, but also easy to read. |
|||
Articles for ''The Medical Letter'' are drafted by either an editor or external consultant using both published and available unpublished studies that are reviewed for methodological rigor with special attention to the results of [[clinical trial]]s. A preliminary draft is circulated to every member of the advisory board and 10-20 other investigators with relevant clinical or experimental experience with the article's topic. Drafts are also provided to the [[Food and Drug Administration]] and [[Centers for Disease Control and Prevention]] and to all first authors of articles cited in the text. The evaluation of each drug includes a discussion of its efficacy, side effects, and a comparison with older, more established agents. The final version of the paper includes comments from the reviewers and is checked and edited for accuracy and readability.<ref>{{cite web |url=http://medlet-best.securesites.com/downloads/Editorialchart.pdf |title=Flowchart of the editorial process |accessdate=2010-06-29 |publisher=[[The Medical Letter, Inc.]] |format=PDF}}</ref> |
|||
== References == |
== References == |
||
Revision as of 20:55, 29 July 2014
| Discipline | Pharmacology |
|---|---|
| Language | English, French, Italian |
| Publication details | |
| History | 1959-present |
| Publisher | |
| Frequency | Biweekly |
| Standard abbreviations | |
| ISO 4 | Med. Lett. Drugs Ther. |
| Indexing | |
| CODEN | MELEAP |
| ISSN | 1523-2859 |
| LCCN | 00211546 |
| OCLC no. | 40606056 |
| Links | |
The Medical Letter on Drugs and Therapeutics is a peer-reviewed biweekly medical publication that provides critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Editorial process
The first draft of an article is prepared by one of our in-house or contributing editors or by an outside expert. This initial draft is edited and sent to our Contributing Editors, to 10-20 other reviewers who have clinical and/or experimental experience with the drug or type of drug or disease under review, to the FDA, and to the first and last authors of all the articles cited in the text. Many critical observations, suggestions, and questions are received from the reviewers and are incorporated into the article during the revision process. Further communication as needed is followed by fact checking and editing to make sure the final appraisal is not only accurate, but also easy to read.